Teva Pharmaceutical Industries (TEVJF) Inventory Average (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Inventory Average across 17 years of filings, most recently posting $3.2 billion for Q1 2026.

• Quarterly Inventory Average rose 1.61% year-over-year to $3.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.2 billion (up 1.61% YoY) and the FY2025 annual result came in at $3.1 billion, down 11.98% from the prior year.
• Inventory Average retreated to $3.2 billion in Q1 2026, from $3.3 billion in the prior quarter.
• Over five years, Inventory Average peaked at $4.1 billion in Q2 2023 and troughed at $3.1 billion in Q1 2025.
• A 5-year average of $3.7 billion and a median of $3.9 billion in 2024 frame the typical range for Inventory Average.
• Annual changes were most pronounced in 2023 — Inventory Average grew 4.94% — and 2025, when it declined 21.53%.
• Tracing TEVJF's Inventory Average over 5 years: stood at $3.8 billion in 2022, then advanced by 4.94% to $4.0 billion in 2023, then fell by 13.7% to $3.5 billion in 2024, then declined by 6.66% to $3.3 billion in 2025, then dropped by 2.26% to $3.2 billion in 2026.
• Business Quant data shows TEVJF's Inventory Average at $3.2 billion in Q1 2026, $3.3 billion in Q4 2025, and $3.4 billion in Q3 2025.